Clinical Trial Update: Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults [Phase 2]

View source ↗

Summary

Phase 2 trial updating safety and tolerability of ruxolitinib in antiretroviral-treated adults with HIV.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED | Results posted: 2019-04-18